Prostate cancer - evidence of exercise and nutrition trial (PrEvENT):Study protocol for a randomised controlled feasibility trial by Hackshaw-McGeagh, Lucy et al.
                          Hackshaw-McGeagh, L., Lane, J. A., Persad, R., Gillatt, D., Holly, J. M. P.,
Koupparis, A., ... Martin, R. (2016). Prostate cancer - evidence of exercise
and nutrition trial (PrEvENT): Study protocol for a randomised controlled
feasibility trial. Trials, 17, [123]. 10.1186/s13063-016-1248-x
Publisher's PDF, also known as Final Published Version
Link to published version (if available):
10.1186/s13063-016-1248-x
Link to publication record in Explore Bristol Research
PDF-document
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms.html
Take down policy
Explore Bristol Research is a digital archive and the intention is that deposited content should not be
removed. However, if you believe that this version of the work breaches copyright law please contact
open-access@bristol.ac.uk and include the following information in your message:
• Your contact details
• Bibliographic details for the item, including a URL
• An outline of the nature of the complaint
On receipt of your message the Open Access Team will immediately investigate your claim, make an
initial judgement of the validity of the claim and, where appropriate, withdraw the item in question
from public view.
STUDY PROTOCOL Open Access
Prostate cancer - evidence of exercise and
nutrition trial (PrEvENT): study protocol for
a randomised controlled feasibility trial
Lucy Hackshaw-McGeagh1,2*, J. Athene Lane1,2, Raj Persad3, David Gillatt3, Jeff M. P. Holly4, Anthony Koupparis3,
Edward Rowe3, Lyndsey Johnston5, Jenny Cloete5, Constance Shiridzinomwa5, Paul Abrams3, Chris M. Penfold1,
Amit Bahl3,6, Jon Oxley7, Claire M. Perks4 and Richard Martin1,2
Abstract
Background: A growing body of observational evidence suggests that nutritional and physical activity
interventions are associated with beneficial outcomes for men with prostate cancer, including brisk walking,
lycopene intake, increased fruit and vegetable intake and reduced dairy consumption. However, randomised
controlled trial data are limited. The ‘Prostate Cancer: Evidence of Exercise and Nutrition Trial’ investigates the
feasibility of recruiting and randomising men diagnosed with localised prostate cancer and eligible for radical
prostatectomy to interventions that modify nutrition and physical activity. The primary outcomes are randomisation
rates and adherence to the interventions at 6 months following randomisation. The secondary outcomes are
intervention tolerability, trial retention, change in prostate specific antigen level, change in diet, change in general
physical activity levels, insulin-like growth factor levels, and a range of related outcomes, including quality of life
measures.
Methods/design: The trial is factorial, randomising men to both a physical activity (brisk walking or control) and
nutritional (lycopene supplementation or increased fruit and vegetables with reduced dairy consumption or
control) intervention. The trial has two phases: men are enrolled into a cohort study prior to radical prostatectomy,
and then consented after radical prostatectomy into a randomised controlled trial. Data are collected at four time
points (cohort baseline, true trial baseline and 3 and 6 months post-randomisation).
Discussion: The Prostate Cancer: Evidence of Exercise and Nutrition Trial aims to determine whether men with
localised prostate cancer who are scheduled for radical prostatectomy can be recruited into a cohort and
subsequently randomised to a 6-month nutrition and physical activity intervention trial. If successful, this feasibility
trial will inform a larger trial to investigate whether this population will gain clinical benefit from long-term
nutritional and physical activity interventions post-surgery.
Prostate Cancer: Evidence of Exercise and Nutrition Trial (PrEvENT) is registered on the ISRCTN registry, ref number
ISRCTN99048944. Date of registration 17 November 2014.
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Background
Prostate cancer is the most common malignancy in men
in the Western world [1], accounting for a quarter of all
new male cancer cases in the United Kingdom [2]. In
many cases, localised prostate cancer is slow growing;
however, an unpredictable proportion of men suffer
more rapidly progressive, fatal disease.
A growing body of observational evidence suggests that
certain nutritional and physical activity interventions are
associated with beneficial outcomes for men with prostate
cancer, such as improved quality of life, longer disease-
free survival and reduced prostate cancer mortality [3, 4].
In addition, a cancer diagnosis can provide a teachable
moment during which an individual may be motivated to
improve their health behaviours [5, 6].
The Prostate Cancer: Evidence of Exercise and Nutrition
Trial (PrEvENT) is a feasibility randomised controlled trial
(RCT). PrEvENT investigates whether men who have
undergone radical prostatectomy will adhere to a nutri-
tional and physical activity intervention and explores
the implications of the intervention on a range of
surrogate outcomes.
The rationale for the interventions included in the trial
is described below.
Physical activity
Observational studies suggest that moderate to vigorous
physical activity is associated with reduced risk of
biochemical recurrence and mortality in men with pros-
tate cancer. For example 3 hours of moderate to vigor-
ous physical activity per week was associated with a
61 % decrease in prostate cancer mortality compared
with less than 1 hour [7]. Prostate cancer most often
becomes evident in older age when men may not always
be able, or motivated, to participate in vigorous activity.
Brisk walking is a potential alternative, as it provides
exposure to moderate-intensity activity [8], and has been
associated with anti-cancer cellular behaviour [9]. Brisk
walking does not require specialised equipment or train-
ing and is not location specific. A higher body mass
index has been associated with poorer prostate cancer
survival suggesting that promotion of physical activity
may reduce cancer progression through weight control
[10]. Guidelines recommend that people with cancer do
30 minutes of moderate-intensity exercise 5 days per
week [11]. However, the majority of men with prostate
cancer do not meet these guidelines [12].
Lycopene
Lycopene is a carotenoid constituent of tomatoes with
potential anti-cancer activity. In an observational study,
men’s intake of tomato sauce following a diagnosis of
prostate cancer was associated with reduced risk of
disease progression [13]. A small trial (n = 81) in men at
high risk of prostate cancer demonstrated the acceptabil-
ity and tolerability of lycopene supplements as tablets
[14]. However, there is limited evidence from RCTs for
the effect of lycopene when used as adjunct therapy in
men with prostate cancer [15].
Plant-based diets
Vegetables and legumes have been associated with a
lower risk of prostate cancer, and in some studies, they
are associated with a reduced risk of advanced or aggres-
sive disease at diagnosis [10, 16]. They are thought to
enhance immunity and inhibit cell growth, and con-
sumption after diagnosis is associated with a reduced
risk of progression [17, 18]. Evidence of the relationship
between fruit intake and prostate cancer progression is
limited. However, both fruit and cruciferous vegetables
are high in vitamin C and increased intake of vitamin C
has been associated with clinical outcomes, such as
reduced prostate cancer risk [19], DNA repair [20] and
maintained levels of PSA in men with biochemical
recurrence of prostate cancer [21].
Dairy products and soy milk
Observational evidence suggests that high intakes of
dairy products and calcium, for example from cow’s
milk, could be associated with a greater risk of prostate
cancer [22, 23], but the evidence is inconclusive [10, 24].
Prostate cancer has been inversely associated with intake
of soya and soya foods [25, 26]. Studies have reported
decreased mean (PSA) levels in men with prostate can-
cer, who were supplemented with soy bread or soy and
linseed bread, compared to supplementation with wheat
bread [27]. Not all trials, however, have reported such
PSA reductions in association with soy protein supple-
mentation [28].
Empirical data informing the trial protocol
We conducted interviews to explore attitudes towards,
and previous experience of, nutrition and physical
activity interventions, as well as opinions about the
proposed PrEvENT trial, with men following radical
prostatectomy for prostate cancer, their partners and
their healthcare professionals. These interviews provided
evidence that although some men may not have much
experience of such interventions, they would attempt to
make changes, especially if they felt it would benefit
them or influence future prostate cancer treatment. They
were positive about the proposed intervention. However,
potential barriers that the men highlighted, including
treatment-related incontinence and aversions to certain
food products were discussed and considered when devel-
oping the PrEvENT intervention. Results from the qualita-
tive interviews are to be published elsewhere (Unpublished
observations, Hackshaw-McGeagh et al.).
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As well as incorporating the World Cancer Research
Fund Continuous Update Project review [10], we under-
took a systematic review of the existing literature on the
effect of dietary, nutritional and physical activity inter-
ventions on clinical outcomes in men with prostate
cancer [29]. This review highlights the paucity of good
quality RCT evidence and supports the development of
feasibility and pilot RCTs to underpin the development
of definitive trials in this area.
Based on existing evidence, we hypothesised that
following radical prostatectomy for localised prostate
cancer, men will accept, and adhere to, nutrition and
physical activity interventions. The feasibility trial was
developed with the intention of informing a larger trial
of these interventions.
Methods/design
Trial setting and participants
The PrEvENT trial has a 2 x 3 factorial design (resulting
in six different experimental conditions), where men are
randomised to levels of both a physical activity and
nutritional intervention. Randomisation is carried out by
the Bristol Randomised Trial Collaboration [30] using a
web based system. Participants and the research team
are not blinded; only the trial statistician will be blinded.
The trial is being conducted under the auspices of the
National Institute for Health Research (NIHR) Bristol
Biomedical Research Unit in Nutrition, Diet and Life-
style [31]. The feasibility trial is being conducted at the
North Bristol National Health Service (NHS) Trust.
Inclusion and exclusion criteria are listed in Table 1.
Trial design
This trial has two phases: i) recruitment of men sched-
uled for radical prostatectomy into a cohort for baseline
and tissue markers and ii) post-radical prostatectomy
recruitment into an RCT. The CONSORT flow diagram,
illustrating passage through the RCT, is shown in Fig. 1.
Initial recruitment phase
Men are recruited to the trial via a consecutive oppor-
tunistic sample; that is, men who are conveniently
accessible to the research team in the urology outpa-
tients clinic and who meet the inclusion criteria are
invited to participate until the sample size is reached
and then are introduced to the study by a member of
the clinical care team at the appointment where a
decision about treatment is made. The expected dur-
ation between the appointment where a decision about
treatment is made and surgery is approximately 4 weeks.
Men who indicate an interest in the trial are directed to
the research nurse for further information and given an
initial research appointment where informed consent
into the cohort is obtained and key data collected. Data
that are obtained include i) a baseline questionnaire,
including collection of information about diet, physical
activity levels, mood and prostate symptoms and ii)
blood samples used to assess baseline levels of nutri-
tional biomarkers and biomarkers of prostate cancer
progression, such as PSA. Men who consent will allow
prostate tissue samples to be obtained from the prostate
that is removed at surgery. The tissue is stored for future
analysis. Full details of data collected at each time point
can be found in Table 2. Each man’s National Health
Service (NHS) number is also recorded for anonymous
data linkage to routine NHS electronic datasets, such as
the Cancer Registries and the Office for National Statistics
Vital Statistics dataset. Recruitment into the cohort study
will continue until the specified sample size (n = 100) has
been reached.
At 5 weeks post-surgery, all men are posted a follow-
up data collection questionnaire and invited to a second
appointment with the research nurse.
Recruitment into the randomised control trial
Men invited to participate in the RCT will have agreed
to be contacted about further related research during
Table 1 PrEvENT inclusion and exclusion criteria
Inclusion criteria
• Clinically localised prostate cancer
• Listed for radical prostatectomy
• Capacity to provide informed consent
• Aged 18 or over
• Sufficient understanding of the English language
Exclusion criteria
• Unable to provide informed consent
• Unsuitable to participate following guidance from their clinician
• Unable to undergo follow-up
• Factors that constrain participation in any aspect of the
intervention, including:
o Co-morbidities, for example:
▪ Congestive heart failure or angina, recent myocardial infarction
or breathing difficulties requiring oxygen use or hospitalisation
o Unable to walk without the aid of a mobility aid (other than
a walking stick)
o Religious beliefs
o Allergy to lycopene
• Current heavy consumers of the nutritional element of the
intervention, that is, taking daily lycopene supplements for more
than 3 months
• Current participation in high levels of regular physical activity, for
example doing strenuous activity five or more times a week for long
enough to work up a sweat
• Any additional reason for not being able to participate in any aspect
of the intervention
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Fig. 1 PrEvENT CONSORT flow diagram
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Table 2 Data collected during PrEvENT
Participant
assessment
Who When
Usual care
team
Consultant Research
nurse
Participant Research
team
Pre-screening Cohort
baseline
appointment
Surgery Cohort
follow-up/true
trial baseline
appointment
6-month
intervention
duration
3-month
follow-up
appointment
6-month
follow-up
appointment
Evaluation
interview
Eligibility screening X X X X
Informed consent X X X X
Demographic data X X X X X
Family medical history X X X X X
Anthropometric data
weight, height, % body fat
X X X X X
Blood sample X X X X
Diet data FFQ [43] X X X X X
Physical activity data
Recent Physical Activity
Questionnaire [44]
X X X X X
Urinary symptoms ICSmale-SF
[45]
X X X X X
Psychological measures
POMS-SF
[46] and Benefit Finding
Scale [47]
X X X X X
Health beliefs data Adapted
from [37] and [32]
X X X X X
Quality of life measures
FACT-P [48]
X X X X X
General health data SF-12 [49] X X X X X
Cancer related fatigue
FACIT-Fatigue [48]
X X X X X
Lifestyle data Drinking
and smoking
X X X X X
Accelerometry data X X X X
Prostate tissue X X
Pedometer data X X
Daily monitoring data Step
count, record of fruit, vegetable,
dairy and lycopene intake
X X
Qualitative evaluation data X X X
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the initial cohort recruitment phase. Along with the post-
surgery follow-up data collection questionnaire, these
men receive an invitation to participate in the RCT. They
are telephoned by the research nurse and screened for
trial eligibility. Inclusion and exclusion criteria for the
RCT can be seen in Table 1. Where eligible, a research
appointment is arranged for the following week, where a
consent form is completed along with collection of blood
samples and provision of an accelerometer (to capture
intensity of physical activity) to wear continuously for the
following week. All men are also provided with a ped-
ometer (to measure daily step count), to wear for the
6-month duration of the trial. The data items that are
being collected are listed in Table 2.
The men are randomised into both the nutritional and
physical activity intervention arms of the trial and
provided with instructions specific to their intervention
allocation. They receive texts, emails and post relating to
the trial interventions, including recipe ideas and motiv-
ational messages, as applicable to their allocated inter-
vention, to encourage continuation of their trial arm
intervention throughout the 6-month trial period. These
contacts take place at 1, 2, 5, 8, 13, 15 and 18 weeks
post-randomisation. They include gratitude for ongoing
support of the research and a reminder of the import-
ance of the data collected. Men are reminded of the
changes they have been asked to make and the data they
have been requested to record daily. Instructions are
given of how to carry out the behaviour change, as well
as being reminded of the potential benefits of the new
behaviour, and men are informed that others similar to
them carry out the intended behaviour. Message content
was developed in line with the Theory of Planned Behav-
iour [32] (See Theoretical Underpinning below).
At 3 and 6 months following randomisation, the men
attend a follow-up research appointment, where repeat
questionnaires are completed. At the 6-month follow-up
appointment, a blood sample is taken. For the final week
of the trial, men wear an accelerometer to record the
intensity of their physical activity.
We intend to recruit 100 men to the cohort, and
of these, randomise at least 80 to the randomised
controlled trial.
Evaluative interviews
Six months following randomisation, a random sample
of men are interviewed to explore their experiences of
the changes they were asked to make to their nutrition
and physical activity, and their experience of participat-
ing in the research.
Withdrawal and discontinuation of participants
Men may be withdrawn from the study by their clinical
care team or the research team if it is considered
detrimental to continue, for example in light of disease
progression. Men who fail to attend appointments are
contacted via telephone to encourage them to attend,
to arrange alternative appointments and to determine
reasons for withdrawal.
Interventions
In the nutritional intervention, men are randomised to
either a lycopene supplement intervention or a plant-
based intervention or a nutritional control arm. The
lycopene intervention involves one 10 mg lycopene
capsule daily (provided to the man). The plant-based
intervention comprises eating as many portions of fruit
and vegetables daily as possible, aiming for at least five
portions, and swapping dairy milk for non-dairy alterna-
tives, for example, soya milk, as often as the men can.
The control arm men carry on with their usual diet; if
the men ask for nutritional advice, standard, publically
available, information is provided.
In the physical activity intervention, men are rando-
mised to either walking at a brisk pace for 30 minutes,
on at least five days a week, on top of their usual phys-
ical activity or to continue with their usual levels of
physical activity.
The men are provided with materials and detailed
instructions specific to their allocated intervention arm
by trained research nurses and asked to follow their
allocated intervention arm for 6 months.
Primary outcome measures
Co-primary outcomes are randomisation rates (the pro-
portion of eligible men who agree to be randomised)
where a rate of 65 % or above would be considered
acceptable [33] and adherence to the interventions at
6 months following randomisation, where a rate of 75 %
or above would be considered acceptable. Adherence
will be calculated for both the nutrition and physical
activity interventions and is taken to be following inter-
vention instructions > 90 % of the time. Adherence to
the nutrition intervention will be assessed by participant
self-report on the daily monitoring form. This form is
completed daily by the participants for the duration of
the 6-month intervention. For the lycopene arm, men
are asked if they took their supplement daily - yes/no;
for vegetable and fruit consumption, men are asked how
many portions they consumed daily; for dairy milk
consumption, men are asked how much of their dairy
milk they replaced with an alternative – all/some/none.
Adherence to the physical activity intervention will be
assessed by their self-reported adherence to the recom-
mended minimum 30 minutes of brisk walking five
times per week during the 6-month intervention phase.
In order to assess the adherence rate with a confidence
interval of ± 5 % and an estimated expected adherence
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rate of 75 %, the required minimum sample size for this
feasibility study would be approximately 75 participants
[34]. Incorporating an expected randomisation rate of
80 %, we intend to recruit at least 100 men into this study.
Secondary outcome measures
The secondary outcomes include intervention tolerabil-
ity (based on qualitative interviews and reported adverse
events), retention (men successfully followed up at
6 months, as a proportion of those who were recruited
to the trial and randomised into a study arm), change in
PSA (a protein produced by cells of the prostate gland,
which is often elevated in men with prostate cancer)
[35] and insulin-like growth factor (IGF-I) levels (raised
IGF-I levels are increasingly being implicated as a poten-
tial risk factor for cancer) [36] and change in all other data
collected between intervention groups at the different
time points. We will explore whether biomarkers of lyco-
pene for the lycopene intervention arm, alpha-carotene,
beta-carotene, lutein, lycopene, total carotenoids and
vitamin C for fruit and vegetable intake, and phyto-
oestrogen, as a biomarker for soya milk, are affected by
the proposed interventions. Full details of the data being
collected at specific time points are described in Table 2.
The study was not powered for secondary outcomes.
Tissue collection
All samples are collected, used and stored in accordance
with the Human Tissue Act 2004. Prostate tissue sec-
tions are formalin-fixed and tissue that is surplus to
diagnostic requirements is stored for later analysis of
nutritional and physical activity biomarkers (including
epigenetic and metabolomic biomarkers) and surrogate
biomarkers of prostate cancer (for example, expression
levels of IGF-I). Stage, margin status and Gleason score
for each radical prostatectomy specimen will be recorded.
Collection of blood samples will allow biological mecha-
nisms linking nutritional, physical activity and other
lifestyle factors with prostate cancer risk and progression
to be further investigated.
Theoretical underpinning
Three psychological theories will be employed during
the PrEvENT trial, each serving a unique purpose. These
are ‘Teachable Moments’ [5], the Transtheoretical Model
of Change (Stages of Change) [37] and the Theory of
Planned Behaviour [32].
Data analysis will allow exploration of whether men
with prostate cancer make naturally occurring changes
to their diet and physical activity as a result of their
cancer diagnosis and treatment. This will assist in estab-
lishing whether receiving a diagnosis of prostate cancer
and undergoing treatment can be utilised as a ‘Teachable
Moment’ [5]. It is hypothesised that prostate cancer
diagnosis is a health event, or Teachable Moment,
thought to motivate individuals to make changes to
health or lifestyle behaviour.
The Transtheoretical Model of Change (Stages of
Change) [37], assesses an individual’s level of readiness to
change. The model categorises people into a number of
stages. Men in the trial will have their readiness to change
assessed at the four data collection time points. Analysis
will then establish whether men, at different levels of
readiness to change, respond differently to the interven-
tion. Additionally, it will be established whether the men’s
level of readiness to change alters during the trial.
The Theory of Planned Behaviour [32] explores three
key considerations which are proposed to influence
whether an individual will make a behaviour change or
not. These are behavioural beliefs, normative beliefs and
control beliefs, which combine to influence intention to
change behaviour. The PrEvENT trial participant-facing
documents have been developed in a manner that
intends to influence these three theoretical consider-
ations, thus helping to implement the behaviour change
in the men, and improve adherence and acceptability of
the interventions.
Analysis plan
The primary comparative analyses will be by intention-
to-treat. Baseline characteristics of each group will be
tabulated using means and standard deviations for
normally distributed data, medians and interquartile
ranges for non-normally distributed data, and percent-
ages and counts for categorical data. Randomisation rate
and adherence to the intervention will both be reported
as a percentage, along with the respective 95 % confi-
dence interval.
We will also conduct exploratory analyses of change in
physical activity and fruit and vegetable consumption (as
measured for adherence to the interventions) will be
analysed using a two-way ANOVAs or appropriate non-
parametric tests if necessary. Change in selected second-
ary outcomes (IGF-I, PSA and blood biomarkers) will be
analysed similarly, although this study is not powered
for secondary outcomes. These analyses will focus on
the main effects of the interventions, but we will also
explore possible interactions between the interventions
with respect to these outcomes. Assuming 80 men are
recruited into the trial, this will provide approximately
90 % power to detect a large main effect size (f = 0.4)
with an alpha level of 0.05, analysing the study as a 2 x 3
factorial design (power will be reduced after correcting
for multiple testing). We will also explore asso-
ciations between baseline Stage of Change; behav-
ioural, normative and control beliefs; and adherence
to the interventions using chi-square tests and logis-
tic regression models.
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Qualitative data collected during this research will be
analysed thematically using a qualitative method, such as
the framework approach [38]. Individuals will not be
identified by name in the written transcript. A qualita-
tive analysis computer programme, such as NVivo [39],
will be used to assist analysis.
The SPIRIT 2013 checklist [40] and the CONSORT
statement [41] were followed and adhered to during the
development of the trial protocol and implementation.
The PrEvENT trial has been given full ethical approval
by Cornwall and Plymouth Research Ethics Committee
(REC), ref: 14/SW/0056, and registered on the ISRCTN
registry, ref number ISRCTN99048944. All participants
provide fully informed consent.
Discussion
Recruitment began in August 2014 (14 months previous
to the time of manuscript submission), and to date, 69
men have been recruited. Initially, recruitment was
intended to be complete within a 6-month period.
However, this is now acknowledged to be an ambitious
estimate. The initial recruitment approach, as described
previously, was at the appointment where a decision
about treatment is made, where eligible men would be
invited into the research by the clinical staff during this
appointment. Initial rates of recruitment were, however,
slower than anticipated, with three men being recruited
on average per month, primarily due to overburden of
the clinical staff. Thus, a different approach to rec-
ruitment is now being taken. Eligible men are identified
through a process of theatre list screening by the
research nurse. Eligible men are contacted via a
consultant-endorsed letter and then telephoned by the
research nurse to be invited into the research. This
method is proving to be fruitful, and recruitment rates
have increased to eight men recruited on average per
month. We now anticipate recruitment to be complete
by January 2016. This is illustrated in Fig. 2.
Summary
The PrEvENT RCT aims to determine whether men with
localised prostate cancer, who are scheduled to undergo
radical prostatectomy, can be recruited into a pre-surgery
cohort and subsequently randomised to a 6-month post-
surgery diet and physical activity intervention trial. The
research additionally aims to determine whether this
population will adhere to their intervention arm, complete
trial documentation as requested and be retained in the
research until the conclusion of the trial. Conclusions
from this feasibility trial, along with previous literature
relating to nutrition and physical activity associations with
prostate cancer risk [29, 42], are intended to inform a
larger longitudinal trial to investigate whether men with
localised prostate cancer, who have undergone radical
prostatectomy, will benefit clinically from long-term diet
and physical activity interventions.
Trial status
The trial began recruitment in August 2014 and recruit-
ment was ongoing at the time of submission.
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